AVC 101
Alternative Names: AVC-101; UniCAR CD123; UniCAR-T-CD123; UniCAR02 T CD123; UniCAR02-TLatest Information Update: 23 Jan 2024
At a glance
- Originator Cellex Patient Treatment
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia
Most Recent Events
- 02 Nov 2023 Updated efficacy and adverse events data from a phase I trial Acute myeloid leukemia presented at the 65th American Society of Hematology Annual Meeting (ASH-2023)
- 05 Apr 2023 AVC 101 is still in phase I trial for Acute myeloid leukaemia (Recurrent, Second-line therapy or greater) in Germany (NCT04230265) (AvenCell Europe pipeline, April 2023)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Recurrent, Second-line therapy or greater) in Germany (IV, Infusion)